SCHEMBL832407

SCHEMBL832407

Cc1ccnc(-c2ccccc2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.50
LMNA P02545 1/20 0.50
MAP4K4 O95819 1/20 0.49
ABL1 P00519 1/20 0.49
LCK P06239 1/20 0.49
FYN P06241 1/20 0.49
IGF1R P08069 1/20 0.49
LTK P29376 1/20 0.49
KDR P35968 1/20 0.49
MAP2K2 P36507 1/20 0.49
MAPK8 P45983 1/20 0.49
MAPK9 P45984 1/20 0.49
CLK2 P49760 1/20 0.49
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49
CDK7 P50613 1/20 0.49
CDK9 P50750 1/20 0.49
CDK5 Q00535 1/20 0.49
MAP2K1 Q02750 1/20 0.49
ACVR1 Q04771 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32526767 1.00 L3MBTL1 (0.50) L3MBTL1LMNAMAP4K4ABL1LCK
SCHEMBL19009228 0.88 LMNA (0.44) L3MBTL1LMNAMAP4K4ABL1LCK
SCHEMBL19037255 0.83 LMNA (0.45) L3MBTL1LMNAMAP4K4ABL1LCK
SCHEMBL17532868 0.83 MEN1 (0.40) L3MBTL1LMNAMAP4K4ABL1LCK
SCHEMBL2678667 0.83 NPC1 (0.51) L3MBTL1LMNAKMT2AMEN1MAPT
SCHEMBL2666244 0.83 MEN1 (0.59) L3MBTL1LMNAMAP4K4ABL1LCK
SCHEMBL31186653 0.82 CYP1A1 (0.46) LMNAMAP4K4ABL1LCKFYN
SCHEMBL23995917 0.81 LMNA (0.46) L3MBTL1LMNAMAP4K4ABL1LCK
SCHEMBL8854902 0.81 MEN1 (0.55) L3MBTL1MAP4K4ABL1LCKFYN
SCHEMBL7964419 0.81 UHRF1 (0.42) KMT2AMEN1MAPTCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2119717-B1 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors BOEHRINGER INGELHEIM INT (DE) 2018-01-17 EP claimed
US-8697868-B2 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-04-15 US claimed
US-20090137801-A1 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 US claimed
EP-1758905-B1 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR BOEHRINGER INGELHEIM INT (DE) 2009-04-29 EP claimed
US-7501426-B2 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-03-10 US claimed
US-20050234108-A1 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US claimed
CN-110088115-B Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device 株式会社半导体能源研究所 2024-05-14 CN disclosed
US-20240109842-A1 ACRYLAMIDE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-04-04 US disclosed
CN-117185884-A Synthesis method of (R) -4-substituted hexahydropyrimidine compound 四川大学 2023-12-08 CN disclosed
US-11818932-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-14 US disclosed
US-20230363260-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-09 US disclosed
US-11807654-B2 Organometallic compound, organic light-emitting device including organometallic compound, and diagnostic composition including organometallic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-11-07 US disclosed
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS INC (US) 2023-09-21 US disclosed
US-20090042873-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2009-02-12 US disclosed
US-20090039776-A1 ORGANOMETALLIC COMPLEX AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME CANON KABUSHIKI KAISHA (JP) 2009-02-12 US disclosed
US-20090039776-A1 ORGANOMETALLIC COMPLEX AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME CANON KABUSHIKI KAISHA (JP) 2009-02-12 US disclosed
WO-2008148840-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-11 WO disclosed
US-20050234108-A1 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US disclosed
CN-1585775-A 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials ORTHO MCNEIL PHARM INC (US) 2005-02-23 CN disclosed
WO-2002076983-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS ITGB6, ITGA5, ITGAV L3MBTL1 2816/4885LMNA 3348/4885MAP4K4 3865/4885
US-20090042873-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE CYP3A5, CYP2C8, PAICS L3MBTL1 4095/4885LMNA 2463/4885MAP4K4 3857/4885
US-20090137801-A1 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS DPP8, DPP4, DPP7 L3MBTL1 3702/4885LMNA 2911/4885MAP4K4 1714/4885
US-11807654-B2 Organometallic compound, organic light-emitting device including organometallic compound, and diagnostic composition including organometallic compound L1CAM, FOXM1, MEN1 L3MBTL1 13/4885LMNA 1196/4885MAP4K4 3927/4885
US-20050234108-A1 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions DPP8, DPP4, DPP7 L3MBTL1 3625/4885LMNA 1878/4885MAP4K4 2098/4885
US-20240109842-A1 ACRYLAMIDE COMPOUNDS HPGDS, MYADM, ACR L3MBTL1 3808/4885LMNA 1924/4885MAP4K4 1205/4885
US-20090039776-A1 ORGANOMETALLIC COMPLEX AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME LAGE3, ORC3, INTS9 L3MBTL1 444/4885LMNA 3712/4885MAP4K4 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.